Evidence map›Paper›PMID 29178616›Full record

ArticleJournal of magnetic resonance imaging : JMRI2018

Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.

Nita Amornsiripanitch, Vicky T Nguyen, Habib Rahbar, Daniel S Hippe, Vijayakrishna K Gadi, Mara H Rendi, Savannah C Partridge

Abstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. MR Imaging Features Predictive of Pathologic Complete Response and Survival Outcomes for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Article
  3. Article
  4. Non-contrast Breast MR Imaging.Radiologic clinics of North America · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Association Between Vascular Index MeasuredFrontiers in oncology · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Perfusion-driven Intravoxel Incoherent Motion (IVIM) MRI in Oncology: Applications, Challenges, and Future Trends.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2021
    Review
  17. Review
  18. Quantitative parameters of MRI andAmerican journal of nuclear medicine and molecular imaging · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nita AmornsiripanitchDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Vicky T NguyenDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Habib RahbarDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Daniel S HippeDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Vijayakrishna K GadiDepartment of Medicine/Oncology, University of Washington, Seattle, Washington, USA.
Mara H RendiDepartment of Pathology, University of Washington, Seattle, Washington, USA.
Savannah C PartridgeDepartment of Radiology, University of Washington, Seattle, Washington, USA.

Funding

Targeted immunotherapy of breast cancer with central memory T cellsP50CA138293 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PORTER, PEGGY L. · 2010 to 2014
$11.0M
MR Diffusion Tensor Imaging for Detection and Characterization of Breast LesionsR01CA151326 · NCI · UNIVERSITY OF WASHINGTON · PI PARTRIDGE, SAVANNAH CORRINA · 2010 to 2014
$1.3M
NCI NIH HHS P50 CA138293NCI NIH HHS R01 CA151326
6 · The paper itself

Abstract

backgroundHormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. PURPOSE: To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk. STUDY TYPE: Retrospective. SUBJECTS: In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health). FIELD STRENGTH/SEQUENCE: Each subject underwent presurgical 3T breast MRI, which included DWI (b = 0, 800 s/mm ASSESSMENT: Apparent diffusion coefficient (ADC) and contrast-to-noise ratio (CNR) were measured for each lesion by a fifth year radiology resident. Pathological markers (Nottingham histologic grade, Ki-67, RS) were determined from pathology reports. Medical records were reviewed to assess recurrence-free survival. STATISTICAL TESTS: RS was stratified into low (<18), moderate (18-30), and high (>30)-risk groups. Associations of DWI characteristics with pathologic biomarkers were evaluated by binary or ordinal logistic regression, as appropriate, with adjustment for multiple comparisons. Post-hoc comparisons between specific groups were also performed.

resultsADCmean (odds ratio [OR] = 0.61 per 1 standard deviation [SD] increase, adj. P = 0.044) and CNR (OR = 1.76 per 1-SD increase, adj. P = 0.026) were significantly associated with increasing tumor grade. DWI CNR was also significantly associated with a high (Ki-67 ≥14%) proliferation rate (OR = 2.55 per 1-SD increase, adj. P = 0.026). While there were no statistically significant linear associations in ADC (adj. P = 0.80-0.85) and CNR (adj. P = 0.56) across all three RS groups by ordinal logistic regression, post-hoc analyses suggested that high RS lesions exhibited lower ADCmean (P = 0.037) and ADCmax (P = 0.004) values and higher CNR (P = 0.008) compared to lesions with a low or moderate RS. DATA

conclusionDWI characteristics correlated with tumor grade, proliferation index, and RS, and may potentially help to identify those with highest recurrence risk and most potential benefit from chemotherapy. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage 3 J. Magn. Reson. Imaging 2017.

Indexed as

Diffusion Magnetic Resonance ImagingAdultAgedAntineoplastic AgentsBiopsyBreast NeoplasmsDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaadjuvant chemotherapybreast cancerdiffusion-weighted imaging (DWI)Oncotype DX 21-gene recurrence scoreprognostic biomarker

Identifiers

PMID29178616
PMCPMC5971126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.